Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Repatoxaban vs Xarelto in Healthy Volunteers
NCT03071380Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Feb 2015
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in thromboembolism (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximal measured plasma concentration, Area under the plasma concentration-time curve from time zero to the last measurable concentration and 1 more. Started Feb 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT03071380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071380.